The pharmaceutical industry, known for its dynamic shifts and competitive landscape, has witnessed a seismic change at its pinnacle. Eli…
Read More
Insilico CEO Sees Potentially $2.75 Billion Collaboration as ‘Fusing Lilly’s Clinical Excellence’ with Insilico’s ‘End-to-End AI Engine’
On March 29, Insilico Medicine, a pioneer in artificial intelligence-driven drug discovery, announced a landmark collaboration with pharmaceutical giant Eli…
Read More
Novo Nordisk’s new weight loss treatment inferior to Lilly’s tirzepatide
A Deep Dive into the Trial Results CagriSema, a novel combination therapy comprising cagrilintide and semaglutide, delivered an average weight…
Read More
Lilly’s triple agonist achieves 16.8% weight loss in phase 3 trial
Eli Lilly’s investigational drug, retatrutide, a pioneering first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist, has delivered extraordinary results…
Read More
Lilly is now the top pharma company by revenue as Mounjaro (+99%) and Zepbound (+175%) combine for $36.5B in FY2025
Eli Lilly and Company has achieved a historic milestone, concluding fiscal year 2025 as the world’s highest-earning pharmaceutical company by…
Read More
Lilly Ascends to Pharma’s Top Revenue Spot Amidst Landmark Oral GLP-1 Approval, Yet Wall Street Remains Unconvinced
Eli Lilly and Company has officially claimed the top spot among global pharmaceutical companies by revenue, a monumental achievement underscored…
Read More
Pharma 50 2026: The top spot in pharma rarely lasts. Lilly is betting it can change that.
Eli Lilly has ascended to the pinnacle of the pharmaceutical industry, claiming the top spot on the prestigious Pharma 50…
Read More
Eli Lilly’s triple agonist achieves 16.8% weight loss in phase 3 trial
Eli Lilly and Company today announced groundbreaking results from a Phase 3 clinical trial, revealing that its investigational triple agonist,…
Read More
Novo Nordisk’s New Weight Loss Treatment CagriSema Shows Inferiority to Lilly’s Tirzepatide in Head-to-Head Trial
Novo Nordisk, a global leader in diabetes and obesity care, announced on Monday that its eagerly anticipated weight loss treatment,…
Read More
Eli Lilly Ascends to Pharmaceutical Revenue Zenith with Oral GLP-1 Approval, Yet Wall Street Remains Unconvinced
Indianapolis, IN – Eli Lilly and Company, a venerable pharmaceutical giant, has officially seized the top position in global pharmaceutical…
Read More
